Todd Anderman Biography and Net Worth

Insider of Ocular Therapeutix

Todd Anderman is Chief Legal Officer and Corporate Secretary of Ocular Therapeutix. Prior to joining the company, Mr. Anderman was Senior Vice President, Chief Legal Officer and Corporate Secretary of Iveric Bio, where he led the company’s legal, intellectual property and compliance functions. Prior to that, Mr. Anderman was a corporate attorney for several years with Wilmer Cutler Pickering Hale and Dorr LLP and Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising biotechnology companies from early-stage startups through product development and eventual commercialization. In addition, Mr. Anderman has advised on numerous merger, acquisition, divestiture, licensing, and financing transactions throughout his career. Mr. Anderman received his BA in Government and Philosophy from the College of Arts & Sciences at Cornell University and his JD from the University of Pennsylvania Law School.

What is Todd Anderman's net worth?: The estimated net worth of Todd Anderman is at least $1.09 million as of October 8th, 2025. Anderman owns 87,568 shares of Ocular Therapeutix stock worth more than $1,088,470 as of December 4th. This net worth estimate does not reflect any other assets that Anderman may own. Learn More about Todd Anderman's net worth.
How do I contact Todd Anderman?: The corporate mailing address for Anderman and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at [email protected]. Learn More on Todd Anderman's contact information.
Has Todd Anderman been buying or selling shares of Ocular Therapeutix?: During the last quarter, Todd Anderman has sold $137,368.88 of Ocular Therapeutix stock. Most recently, Todd Anderman sold 11,132 shares of the business's stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $12.34, for a transaction totalling $137,368.88. Following the completion of the sale, the insider now directly owns 87,568 shares of the company's stock, valued at $1,080,589.12. Learn More on Todd Anderman's trading history.
Who are Ocular Therapeutix's active insiders?: Ocular Therapeutix's insider roster includes Todd Anderman (Insider), Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Peter Kaiser (Chief Development Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.
Are insiders buying or selling shares of Ocular Therapeutix?: During the last year, Ocular Therapeutix insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $69,600.00. During the last year, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 129,780 shares worth more than $1,220,159.39. The most recent insider tranaction occured on October, 8th when insider Todd Anderman sold 11,132 shares worth more than $137,368.88. Insiders at Ocular Therapeutix own 2.3% of the company. Learn More about insider trades at Ocular Therapeutix.
Information on this page was last updated on 10/8/2025.

Todd Anderman Insider Trading History at Ocular Therapeutix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/8/2025	Sell	11,132	$12.34	$137,368.88	87,568

Todd Anderman Buying and Selling Activity at Ocular Therapeutix

Ocular Therapeutix Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $12.43

$11.41

$13.00

50 Day Range

MA: $11.63

$10.63

$12.53

2 Week Range

Now: $12.43

$5.78

$13.85

Volume

5,820,311 shs

Average Volume

2,330,914 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96